A Randomized, Double-Blind, Placebo-Controlled Trial of Simvastatin on Subarachnoid Hemorrhage-Induced Vasospasm
To determine whether HMG-CoA reductase inhibitor simvastatin prevents or ameliorates subarachnoid hemorrhage-induced delayed vasospasm and its ischemic consequences.
The mortality rate of aneurysmal subarachnoid hemorrhage (SAH) approaches 50% within the 1st 24 hours of ictus. Patients who survive can subsequently develop a progressive vasospasm of large cerebral arteries, which is a major cause of morbidity and mortality. Vasospasm can be of varying severity, and only a small portion of patients with vasospasm develop clinical signs or symptoms. Patients with severe vasospasm are prone to develop ischemic deficits, which, if untreated, will progress into ischemic infarcts.
The mechanisms of vasospasm have been subject to intense investigation. Nitric oxide (NO)-cGMP system has attracted particular attention. Under normal physiological conditions, NO synthesized by endothelia NO synthase (eNOS) stimulates vascular smooth muscle cGMP production, which in turn causes smooth muscle relaxation. Vasospasm impairs endothelium-dependent dilations, suggesting that SAH induces a state of NO deficiency within cerebral arteries.
There are several potential mechanisms of such an NO deficiency. Hemoglobin is a potent scavenger of NO, and when applied extraluminal it binds NO and inhibits its action. Presence of perivascular hemoglobin may contribute to development of vasospasm by reducing the availability of NO. It has been shown that adventitial applied hemoglobin can inhibit basal NO activity and that in vivo adventitial exposure to whole blood leads to a reduction in basal cGMP levels in association with vasospasm of cerebral arteries. Similarly, superoxide also reacts with NO and acts as an NO scavenger. Superoxide production is increased after SAH, which may in part be responsible for inhibition of NO-dependent vasodilation. Free radical scavengers and manipulations to reduce free radical formation reduce vasospasm after SAH.
NOS is constitutively expressed in endothelium and adventitial perivascular nerve fibers. SAH-induced vasospasm in monkeys has been associated with diminished constitutive NOS immunoreactivity in the perivascular nerves around the spastic arteries. Endothelial NOS mRNA has also been decreased in monkey cerebral arteries 7d after SAH. Therefore, data suggest that there is a relative reduction in NO synthesis after SAH, in addition to increased breakdown.
In summary, the reduction in NO tonus around the cerebral arteries induced by decreased expression of endothelial NOS as well as increased NO scavenger substances in the subarachnoid space, and a relative resistance to NO-induced vasodilation in SAH appears to be one of the key events in the development of vasospasm. Therefore, therapeutic interventions that enhance endothelial NO production may compensate for these changes and reverse or reduce vasospasm.
Statins are FDA approved mainly as antihyperlipidemics, and they effectively reduce the risk of stroke and myocardial infarction. Simvastatin is also FDA-approved for stroke prevention. The risk reduction, however, is not correlated with the degree of lipid reduction, and is seen even in individuals with normal lipid levels. Statins are also cerebroprotective in stroke. They enhance endothelium-dependent relaxations, augment cerebral blood flow, reduce cerebral infarct size, and improve neurological outcome of stroke in normocholesterolemic animals. Their protective effects are independent of lipid reduction. Most importantly, statins upregulate endothelial NOS expression. This in turn improves cerebral blood flow and reduces infarct size in experimental models. In addition, statin treatment enhances endothelial fibrinolytic action, and inhibits platelet aggregation. Therefore, statins are excellent candidates to test on SAH-induced vasospasm.
This study has a randomized, double blind, placebo-controlled design. The anticipated enrollment is 104 patients, 52 in simvastatin, and 52 in placebo group, all recruited and studied at MGH. Assuming a difference of 27% or more, the power of this study is 88%, and alpha=0.05.
Inclusion and exclusion criteria are summarized below. Once enrolled, patients are randomized by Research Pharmacy staff to receive either placebo, or simvastatin 80 mg once every day, the highest clinically used dose of simvastatin. We chose this dose to maximize the effect on endothelium, which has been dose dependent in experimental studies. The study investigators are blinded to the treatment group. Patients are followed prospectively and receive standard aneurysmal subarachnoid hemorrhage care. The data collected pertains to development of vasospasm, and hence involves daily vital signs, neurologic examination, and routine neuroimaging. The development of vasospasm is determined based on daily transcranial Doppler studies, conventional angiography (routinely done within 7 days after subarachnoid hemorrhage as standard of care), and neurologic examination. Liver function tests along with total CPK are checked on admission and once a week for as long as the drug is continued, to screen for potential toxicity from the medication. Medication is discontinued if CPK or liver enzymes are elevated by more than 3 times the upper limit of normal range. CPK elevations due to surgical or percutaneous/endovascular interventions, or from cardiac sources (i.e. accompanied by troponin elevation with or without ECG changes), are not considered as indications for drug discontinuation.
Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Massachusetts General Hospital
Brigham and Women's Hospital
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT00235963
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
Subarachnoid Hemorrhage, Traumatic
Bleeding into the SUBARACHNOID SPACE due to CRANIOCEREBRAL TRAUMA. Minor hemorrhages may be asymptomatic; moderate to severe hemorrhages may be associated with INTRACRANIAL HYPERTENSION and VASOSPASM, INTRACRANIAL.
Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6)
Intracranial Hemorrhage, Traumatic
Bleeding within the SKULL induced by penetrating and nonpenetrating traumatic injuries, including hemorrhages into the tissues of CEREBRUM; BRAIN STEM; and CEREBELLUM; as well as into the epidural, subdural and subarachnoid spaces of the MENINGES.
Abnormal sensitivity to light. This may occur as a manifestation of EYE DISEASES; MIGRAINE; SUBARACHNOID HEMORRHAGE; MENINGITIS; and other disorders. Photophobia may also occur in association with DEPRESSION and other MENTAL DISORDERS.
The purpose of this study is to test whether treatment with a drug called Simvastatin prevents and improves outcome in patients who have Subarachnoid bleeding. Simvastatin is currently app...
Experimental evidences supported the benefit of Simvastatin in subarachnoid haemorrhage. Moreover, Simvastatin is a potent agent in achieving low-density lipoprotein (LDL) reduction with a...
The purpose of this study is to determine if giving blood transfusions to anemic patients with subarachnoid hemorrhage will reduce their chances of having a stroke from vasospasm.
Extensive research has shown that the big event that leads to the initiation of vasospasm is the release of oxyhemoglobin (blood breakdown product).Depletion of NO synthase (19,20,21) was...
The purpose of this study is to evaluate the tolerability and safety of 25 percent human albumin therapy in patients with subarachnoid hemorrhage.
BACKGROUND: A pretruncal subarachnoid hemorrhage has been accepted as a "benign" entity. Here we present two patients with delayed cerebral infarction following pretruncal subarachnoid hemorrhage. MET...
Hypovolemia is common after subarachnoid hemorrhage, and fluid imbalance negatively affects clinical outcome. Standard bedside volume measures fail to adequately assess fluid status after subarachnoid...
Subarachnoid hemorrhage is characterized by the extravasation of blood into the spaces covering the central nervous system which are filled with cerebrospinal fluid. The leading cause of non-traumatic...
The determinants of subarachnoid hemorrhage (SAH) volume and an atypical pattern of blood are not clear. Our objective was to determine if reduced platelet activity on admission and abnormal venous dr...
Cardiopulmonary complications after aneurysmal subarachnoid hemorrhage negatively affect overall morbidity and mortality. An electronic literature search was performed for English-language articles fo...